LHXL3HARRIS TECHNOLOGIES, INC....

NYSE l3harris.com


$ 230.22 $ 1.00 (0.44 %)    

Friday, 02-Aug-2024 15:59:56 EDT
QQQ $ 447.95 $ -3.89 (-0.86 %)
DIA $ 397.31 $ -6.10 (-1.51 %)
SPY $ 532.92 $ -10.09 (-1.86 %)
TLT $ 98.17 $ 2.86 (3 %)
GLD $ 225.36 $ -0.41 (-0.18 %)
$ 230.19
$ 229.23
$ 230.19 x 100
-- x --
$ 226.38 - $ 232.82
$ 157.61 - $ 245.60
1,014,741
na
43.48B
$ 0.87
$ 36.54
TBD
na
na ($ 0.02)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 07-26-2024 06-28-2024 10-Q
2 04-26-2024 03-29-2024 10-Q
3 02-20-2024 12-29-2023 10-K
4 10-27-2023 09-29-2023 10-Q
5 07-26-2023 06-30-2023 10-Q
6 04-28-2023 03-31-2023 10-Q
7 02-24-2023 12-30-2022 10-K
8 10-31-2022 09-30-2022 10-Q
9 07-29-2022 07-01-2022 10-Q
10 04-29-2022 04-01-2022 10-Q
11 02-25-2022 12-31-2021 10-K
12 10-29-2021 10-01-2021 10-Q
13 08-04-2021 07-02-2021 10-Q
14 05-03-2021 04-02-2021 10-Q
15 03-01-2021 01-01-2021 10-K
16 11-02-2020 10-02-2020 10-Q
17 08-04-2020 07-03-2020 10-Q
18 05-07-2020 04-03-2020 10-Q
19 03-03-2020 01-03-2020 10-K
20 10-31-2019 09-27-2019 10-Q
21 08-22-2019 06-28-2019 10-K
22 05-02-2019 03-29-2019 10-Q
23 01-30-2019 12-28-2018 10-Q
24 10-26-2018 09-28-2018 10-Q
25 08-27-2018 06-29-2018 10-K
26 05-03-2018 03-30-2018 10-Q
27 01-31-2018 12-29-2017 10-Q
28 10-31-2017 09-29-2017 10-Q
29 08-29-2017 06-30-2017 10-K
30 05-03-2017 03-31-2017 10-Q
31 02-03-2017 12-30-2016 10-Q
32 11-02-2016 09-30-2016 10-Q
33 08-29-2016 07-01-2016 10-K
34 05-04-2016 04-01-2016 10-Q
35 02-03-2016 01-01-2016 10-Q
36 11-06-2015 10-02-2015 10-Q
37 08-31-2015 07-03-2015 10-K
38 05-06-2015 04-03-2015 10-Q
39 02-10-2015 01-02-2015 10-Q
40 10-29-2014 09-26-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 wells-fargo-maintains-overweight-on-l3harris-technologies-lowers-price-target-to-260

Wells Fargo analyst Matthew Akers maintains L3Harris Technologies (NYSE:LHX) with a Overweight and lowers the price target f...

 barclays-maintains-overweight-on-l3harris-technologies-raises-price-target-to-265

Barclays analyst David Strauss maintains L3Harris Technologies (NYSE:LHX) with a Overweight and raises the price target from...

 rbc-capital-reiterates-outperform-on-l3harris-technologies-maintains-250-price-target

RBC Capital analyst Ken Herbert reiterates L3Harris Technologies (NYSE:LHX) with a Outperform and maintains $250 price target.

 susquehanna-maintains-positive-on-l3harris-technologies-raises-price-target-to-270

Susquehanna analyst Charles Minervino maintains L3Harris Technologies (NYSE:LHX) with a Positive and raises the price target...

 harris-or-trump--defense-stocks-are-winning-tech-battle-personal-income-drops-trump-crypto-push

To gain an edge, this is what you need to know today.

 deutsche-bank-downgrades-l3harris-technologies-to-hold-raises-price-target-to-257

Deutsche Bank analyst Scott Deuschle downgrades L3Harris Technologies (NYSE:LHX) from Buy to Hold and raises the price targe...

 l3harris-technologies-q2-earnings-eps-beat-revenue-up-13-guidance-raise-and-more

L3Harris said second-quarter revenue increased 13% year-over-year to $5.3 billion, which was in line with consensus estimates, ...

 l3harris-technologies-raises-fy24-eps-guidance-from-1270-1305-to-1285-1315-vs-1297-est-revenue-guidance-from-208b-213b-to-21b-213b-vs-2121b-est

SUMMARY FINANCIAL RESULTS AND 2024 GUIDANCE                  Second Quarter Year to Date 2024

 l3harris-technologies-q2-adj-324-beats-317-estimate-sales-530b-inline

L3Harris Technologies (NYSE:LHX) reported quarterly earnings of $3.24 per share which beat the analyst consensus estimate of $3...

 how-to-earn-500-a-month-from-l3harris-technologies-stock-ahead-of-q2-earnings-report

L3Harris currently has a dividend yield of 1.96%. That's a quarterly dividend amount of $1.16 a share. Here's how you c...

 l3harris-technologies-boeing-787-9-full-flight-simulator-enters-into-service-at-anas-tokyo-training-centre

- Reuters 

 pfizer-l3harris-technologies-and-more-cnbcs-final-trades

Pfizer selected Danuglipron, its once-daily weight loss drug, for continued advancement based on an ongoing pharmacokinetic study.

Core News & Articles

- Reuters

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION